Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab plus glaucoma eye drops in neovascular age-related macular degeneration
jRCTs031260199Recruiting
- Sponsor
- HOYA
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of faricimab in exudative macular degeneration (3 arms), sponsored by HOYA. Primary endpoint: Faricimab concentration in aqueous humor. Started Jun 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCTs031260199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260199.